ArticleInternational journal of molecular sciences2023
Transcriptomic Analysis of Hidradenitis Suppurativa: A Unique Molecular Signature with Broad Immune Activation.
Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.
- Investigating the Inflammatory Link Between Vitamin D and Hidradenitis Suppurativa: A Systematic Review and Causal Inference Analysis.International journal of molecular sciences · 2026Pooled it
- Redundant γc cytokines license IL-1-driven neutrophil inflammation through MEK/ERK convergence.bioRxiv : the preprint server for biology · 2026Article
- Article
- A Neuroendocrine-Immune Model of Hidradenitis Suppurativa: Mechanistic Insights into Pain, Pruritus, and Hormonal Triggers.Journal of clinical medicine · 2026Review
- Transcriptomic Signatures and Molecular Pathways in Hidradenitis Suppurativa-A Narrative Review.International journal of molecular sciences · 2025Review
- Combined TNF-α and OX40L targeting as a new treatment option for hidradenitis suppurativa.The journal of allergy and clinical immunology. Global · 2025Article
- IRAK4 Targeting: A Breakthrough Approach to Combat Hidradenitis Suppurativa.Biologics : targets & therapy · 2025Review
- Transcriptomic profiling reveals distinct molecular signatures among lesion types in hidradenitis suppurativa.Frontiers in immunology · 2025Article
- Unlocking the Mechanisms of Hidradenitis Suppurativa: Inflammation and miRNA Insights.Clinical, cosmetic and investigational dermatology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hidradenitis suppurativa is a chronic inflammatory skin disease with limited treatment options. The poorly understood pathogenesis hinders the development of effective treatments; therefore, a pressing need exists to further elucidate the molecular mechanisms in hidradenitis suppurativa. This study investigated the underlying inflammatory pathways and cell types in hidradenitis suppurativa using transcriptomic approaches with RNA sequencing of lesional and non-lesional skin biopsies from hidradenitis suppurativa, which was jointly analyzed with previously published transcriptomic data from atopic dermatitis and psoriasis patients. The differential expression and pathway enrichment analyses demonstrated the activation of multiple inflammatory processes, including the innate and adaptive immune systems, implicated in the hidradenitis suppurativa pathogenesis. In agreement, hidradenitis suppurativa exhibited a unique and heterogeneous cell type signature involving lymphoid and myeloid cells such as B cells and macrophages. Furthermore, hidradenitis suppurativa displayed increased expression of T
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.